CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-01 | Burrell Terry-Ann Director | Grant or award | +1,467 | 56,314 | ||
| 2024-03-28 | Gibson Christopher Chief Executive Officer | Gift 10b5-1 | −25,000 | 1,083,524 | ||
| 2024-03-28 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −40,000 | $10.10 | $404K | 1,043,524 |
| 2024-03-28 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +25,000 | 25,000 | ||
| 2024-03-28 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −25,000 | $10.10 | $253K | 0 |
| 2024-03-28 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Class B Common Stock 10b5-1 | −25,000 | 92,875 | ||
| 2024-03-21 | Marriott Tina President and COO | Exercise or conversion 10b5-1 | +8,000 | $1.06 | $8K | 647,982 |
| 2024-03-21 | Marriott Tina President and COO | Sale 10b5-1 | −7,390 | $10.70 | $79K | 640,592 |
| 2024-03-21 | Marriott Tina President and COO | Sale 10b5-1 | −610 | $11.34 | $7K | 639,982 |
| 2024-03-21 | Marriott Tina President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −8,000 | 488,000 | ||
| 2024-03-19 | Borgeson Blake Director | Sale 10b5-1 | −20,054 | $10.79 | $216K | 7,252,755 |
| 2024-03-13 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 1,229,179 |
| 2024-03-13 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $11.03 | $276K | 1,204,179 |
| 2024-03-13 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 885,135 | ||
| 2024-03-12 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 1,216,679 |
| 2024-03-12 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $10.46 | $261K | 1,191,679 |
| 2024-03-12 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 922,635 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Conversion | +10,000 | 1,114,919 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Gift | −10,000 | 1,104,919 | ||
| 2024-03-06 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +31,250 | $2.48 | $78K | 1,136,169 |
Page 22 of 41 · 805 trades